|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||63.97 - 66.17|
|52-week range||63.01 - 101.24|
|Beta (5Y monthly)||1.25|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Every investor in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) should be aware of the most powerful shareholder groups...
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.